Comparative economic analyses of minimally invasive direct coronary artery bypass surgery  by Gray, Darryl T. & Veenstra, David L.
Comparative economic analyses of minimally invasive
direct coronary artery bypass surgery
Darryl T. Gray, MD, ScDa,b
David L. Veenstra, PharmD, PhDb,c
Objective: This study was undertaken to assess the degree to which published cost
comparisons of minimally invasive direct coronary artery bypass through a thora-
cotomy versus conventional coronary artery bypass grafting, off-pump bypass
surgery through a sternotomy, or angioplasty with or without stenting adhered to
existing guidelines for performing economic analyses.
Methods: We used minimally invasive direct coronary artery bypass (MIDCAB),
off-pump bypass surgery, cost-effectiveness, economic analysis, and related key-
words to search MEDLINE, other literature databases and article reference lists for
English-language economic analyses of minimally invasive direct coronary artery
bypass procedures versus other procedures that were published from 1990 to
February 2002. We critically appraised article adherence to a 10-item methodologic
checklist modified to address issues particularly relevant to minimally invasive
direct coronary artery bypass evaluations. Assessment discordance was reconciled
by consensus.
Results: Ten articles published from June 1997 to March 2001 compared costs and
(generally) outcomes of minimally invasive direct coronary artery bypass with those
of other procedures. All were nonrandomized comparisons, generally of concurrent
intrainstitutional clinical series. Stated results generally favored minimally invasive
direct coronary artery bypass, angioplasty, or off-pump bypass surgery through a
sternotomy relative to conventional coronary artery bypass grafting. Studies ade-
quately addressed an average of only 24% of applicable checklist items (range
0%-67%). Few studies adequately ensured the comparability of treatment groups,
clearly performed intent-to-treat analyses, comprehensively and credibly measured
costs that were considered, or clearly addressed costs and results of preprocedural
angiography or postprocedural imaging. Only 1 study compared success of revas-
cularization between minimally invasive direct coronary artery bypass and compet-
ing alternatives. No studies specified the cost-analysis perspective or included costs
of physician or physician assistant care.
Conclusions: Most published comparative economic analyses of minimally invasive
direct coronary artery bypass have failed to adequately address issues crucial to such
evaluations. Future studies should more closely follow well-described principles of
clinical epidemiology and cost-effectiveness analysis.
The procedure hereafter described as minimally invasive direct coro-nary artery bypass surgery (MIDCAB)1 revascularizes the distribu-tion of the left anterior descending coronary artery through a thora-cotomy, without using cardiopulmonary bypass. MIDCABimmobilizes the beating heart with devices such as the CTS-2pressure stabilizer (Guidant Corporation, Indianapolis, Ind). MID-
CAB is controversial2 as an alternative to off-pump bypass through a sternotomy
(OPCAB) with the Octopus stabilizer (Medtronic, Inc, Minneapolis, Minn) or to
conventional procedures, including conventional on-pump coronary artery bypass
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grafting (C-CAB) and percutaneous transluminal coronary
angioplasty (PTCA) with or without stenting. It typifies new
technology for which financial as well as clinical implica-
tions must now be evaluated.3 The medical literature in-
creasingly includes economic analyses,4 and guidelines for
conducting and reporting such studies have long been avail-
able.5-10 We originally envisioned assessing the cost-effec-
tiveness of MIDCAB through a systematic review11 of
published comparative economic analyses. However, re-
view of sample MIDCAB evaluations showed widespread
variations in study design, procedures compared, and target
populations, as well as significant methodologic weaknesses
that precluded formal aggregation of study results. We
therefore postulated that formal assessment of existing
MIDCAB cost comparisons would find minimal adherence
to published guidelines for performing such studies.
Methods
Article Identification
We searched the English-language medical literature for 1990 to
2002 to identify original economic analyses evaluating MIDCAB
versus alternative procedures such as OPCAB, C-CAB, PTCA
alone and/or PTCA with stenting. We used MEDLINE to search
titles, abstracts, and keyword lists for the following terms: [mini-
mally invasive bypass surgery OR MIDCAB OR off-pump by-
pass] AND [cost OR cost-effectiveness OR economic analysis OR
cost-benefit analysis]. We reviewed the identified articles, their
reference lists, and MEDLINE-designated “related articles.” We
also searched the Cochrane Collaboration and the British National
Health Service Economic Evaluation databases. We excluded clin-
ical comparisons that did not address costs, studies that evaluated
OPCAB but not MIDCAB, technical notes, case reports, case
series, review articles, abstracts, and letters.
Checklist Design
We assessed the methodologic quality of articles meeting our
inclusion criteria by applying a 1996 checklist published by Drum-
mond and associates9 to issues particularly relevant to MIDCAB
evaluations. The checklist questions as applied herein are de-
scribed as follows:
1. Was a well-defined question posed in answerable form?
Ideally the question should have specified the clinical strategies
compared, time horizons, measures of clinical effectiveness, target
patient populations, and cost-analysis perspective. A sample state-
ment might run as follows: “We analyzed initial revascularization
procedures performed for clinically significant stenosis restricted
to the left anterior descending coronary artery distribution. From a
societal medical care perspective, we assessed the cost-effective-
ness of diagnostic catheterization followed by MIDCAB versus
diagnostic catheterization followed by angioplasty and stenting in
providing 2-year survival free from repeat revascularization pro-
cedures.” Studies were considered adequate if the question was
clearly defined even if it was limited in scope (eg, only considering
inpatient outcomes).
2. Were comprehensive descriptions of the competing alter-
natives given? Cost-effectiveness analyses are intrinsically com-
parative. Interventions can only be cost-effective relative to alter-
natives specified in the analysis. MIDCAB and OPCAB differ in
chest incisions, stabilizers used, potentially treatable vessels, and
results. Therefore studies that included both procedures had to
distinguish clearly between them to receive full credit. Similarly,
because device costs and potential outcomes of PTCA with stent-
ing differ from those of PTCA alone,12 studies comparing both
procedures with MIDCAB had to consider these percutaneous
approaches separately. We did not require specification of the
rationale for excluding specific possible options (eg, considering
OPCAB but not PTCA).
3. Was the effectiveness of the program or service estab-
lished? For at least partial credit, studies had to analyze compet-
ing procedures’ success in achieving their clinical objective of
revascularizing ischemic myocardium. This could have involved
assessment of success through such measures as intraprocedural
angiography,13 intravascular ultrasonography, subsequent tread-
mill testing, and/or freedom from reintervention observed during
specified postprocedural follow-up intervals. Although compari-
sons of patient-perceived outcomes (eg, quality-adjusted survival)
were considered ideal,10 they were not required. Assessments of
perioperative mortality or other complications address procedure
safety but were not considered adequate to measure procedure
effectiveness.
Outcome and cost differences must be reasonably ascribable to
treatment, rather than other factors. Although heretofore uncom-
mon in procedure evaluations,14 this assessment is best achieved
by randomly allocating patients to the therapies being compared.15
Nonrandomized comparisons may suffer from confounding by
clinical indication,16 in which clinical features influencing treat-
ment choices also affect outcome independent of any actual treat-
ment effect. For example, in concurrent intrainstitutional nonran-
domized comparisons, eligible patients presumably underwent
MIDCAB. Patients ineligible for MIDCAB (eg, because of mul-
tivessel disease) who underwent OPCAB or C-CAB differed from
those undergoing MIDCAB in clinically important ways, thus
confounding assessment of treatment effects. Conversely, results
for patients who underwent stenting of arteries generally inacces-
sible by MIDCAB (eg, the circumflex coronary artery) would be of
limited relevance in MIDCAB comparisons. The evolution of
PTCA altered the indications for single-vessel C-CAB,17 and sim-
ilar selective referral could complicate MIDCAB studies.
To establish procedural effectiveness, nonrandomized studies
of MIDCAB had to minimize such confounding. This could have
been achieved by studying control patients treated in time frames
or institutions without MIDCAB (while adjusting for resulting
center effects, secular trends, etc) by restricting analyses to pa-
tients eligible for both MIDCAB and other procedures, for exam-
ple, because of the presence of isolated left anterior descending
coronary artery disease, or by other design approaches. Given the
potential for confounding, reporting treatment group comparability
on relevant parameters (eg, vessels treated, gender, age, and dia-
betes status) was considered essential. However, the mere absence
of statistically significant differences in measured factors would
not have proven treatment group similarity,18 especially in studies
with limited statistical power. This approach would also be ques-
tionable unless measured variables captured key patient character-
istics (eg, target vessel distribution) that would have influenced
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original treatment choice as well as outcome. Alternatively, studies
could have adjusted for residual confounding with logistic regres-
sion, propensity scoring, or other analytic approaches.19
To answer questions of cost-effectiveness, studies also had to
follow the intent-to-treat principle.20 The primary analysis should
have ascribed to the original treatment group all costs and out-
comes of patients in whom any revascularization attempt was
aborted or converted to another procedure. It was considered
inappropriate to exclude such patients or to ascribe their results to
the second procedure performed.
4. Were all the important and relevant costs and conse-
quences for each alternative identified? Studies were assessed on
their capture of costs relevant to the (apparent) analytic perspec-
tive. For example, hospital perspective analyses should have esti-
mated institutional costs, including stabilizer purchase prices and
hospital overhead. If applicable, analyses should also have in-
cluded cost implications of maintaining cardiopulmonary bypass
standby capability during MIDCAB and of reusing disposable
stabilizers. Whereas studies taking the hospital perspective would
appropriately have excluded costs of care provided by nonsalaried
physicians or physician assistants, they should have included costs
of such personnel if they were hospital employees.
Because preoperative diagnostic catheterizations can be per-
formed before or during the surgical admission, catheterization
costs should have been consistently included or excluded for
surgical patients. Because costs of diagnostic catheterization can-
not be separated from those of angioplasty or stenting performed
during the same procedure, comparisons of MIDCAB versus per-
cutaneous revascularization should have included diagnostic cath-
eterization costs for both strategies. Results and costs of assessing
success of the revascularization with intraprocedural imaging,
follow-up treadmill testing, and so on should have been consis-
tently included or excluded for all study patients.
Comparisons of medical costs from a societal perspective
would properly have included costs generated by cardiologists,
cardiac surgeons, anesthesiologists, and radiologists, and costs of
physician- or hospital-employed physician assistants if applicable.
Operating room times that differed for MIDCAB, OPCAB, and
C-CAB would have generated cost differences reflecting variable
durations of anesthesiologist and surgeon involvement. Excluding
costs similar for both procedures (eg, surgeon reimbursement)
might not have affected societal perspective cost differences. How-
ever, if frequencies of repeated procedures or treated complica-
tions differed, then ignoring surgeon costs would have distorted
treatment strategy costs. Although it is recommended,10 analyses
were not required to take broader societal perspectives that would
have included patient out-of-pocket costs, nonmedical economic
costs of lost productivity, and so on.
The study design should also have reasonably captured the
range of clinical outcomes considered. Such follow-up would
ideally have tracked outcomes for several months after the initial
revascularization. Even studies that analyzed only short-term com-
plications needed sufficient follow-up (eg, 30 days) to capture their
frequency, outcomes, and costs.
5. Were costs and consequences measured accurately in ap-
propriate units? Currency is the best measure of costs and should
have been expressed with stated foreign exchange rates if appli-
cable. Resource use should also have been measured separately in
appropriate units (eg, length of total hospital stay in days) to allow
readers to consider how unit costs in their own institutions might
affect study results. Similarly, outcomes such as clinical success
should have been captured by proportions of patients with suc-
cessful revascularization measured by intraprocedural imaging,
freedom from repeat revascularization, and so on. Major compli-
cations (eg, recurrent bleeding necessitating reoperation) should
have been distinguished from minor wound infections and other
minor complications. Studies capturing subsequent revasculariza-
tions should have explicitly focused on repeat procedures involv-
ing the original anatomic site rather than new lesions. Studies also
needed to identify one primary outcome measure (eg, a composite
such as 1-year survival free of repeat revascularization) for use in
calculating cost-effectiveness ratios (described under question 8).
6. Were the costs and consequences considered valued cred-
ibly, given the (apparent) cost perspective? Studies reporting
hospital costs needed to specify the basis for cost estimates (eg,
true production costs or hospital-wide or department-specific cost-
to-charge ratios).21 Studies measuring societal perspective medical
care costs should have combined hospital production costs or
reimbursement with physician cost estimates reflecting Resource
Based Relative Value Scales,22 patient care time multiplied by
compensation and practice expenses expressed per unit time, re-
imbursement (eg, Medicare fee schedules), or other measures.
From no perspective would billed charges adequately represent
costs,23 because charges capture neither the true cost of providing
care nor the reimbursement actually paid.
Costs for care provided in different calendar years should have
been expressed in constant-year dollars (eg, 1998 dollars), based
on the Consumer Price Index.24 Measured outcomes should also
have been captured comprehensively. For example, analyses that
captured postdischarge outcomes and costs should have included
admissions to other facilities (eg, through review of referring
cardiologist office records).
7. Were costs and outcomes adjusted for differential timing?
Costs observed beyond 1 year of follow-up for individual patients
should have been discounted to current value (eg, at 3%/year).
Discounting is independent of inflation and reflects time prefer-
ences related to foregone potential interest or investment income
associated with receiving a given dollar amount in a future year
rather than today. For studies that followed up individual patients
for less than 1 year, discounting was deemed not applicable.
Discounting of future treatment effects10 is still controversial and
was not required.
8. Was an incremental analysis of costs and consequences of
alternatives performed? Ideally, studies would have measured
both costs and clinical effectiveness. Those that found one treat-
ment to be more expensive but more effective should have pre-
sented incremental cost-effectiveness ratios (ICERs), which iden-
tify net cost increases relative to net improvements in outcome. For
example, studies finding that MIDCAB generated a greater 1-year
survival free of repeated revascularization but at higher costs than
PTCA with or without stenting would express these results as
MIDCAB’s mean incremental costs per added year of reinterven-
tion-free survival.
MIDCAB studies that considered inpatient survival and com-
plications (rather than success rates) could only measure incre-
mental costs per added uncomplicated live discharge. This ratio
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does not capture incremental costs associated with successful
myocardial revascularization. Therefore, authors of such studies
were given credit for just presenting absolute or relative differ-
ences in mean costs per patient.
One procedure could be superior to the alternative in either the
cost or outcome dimension and also be at least as good, if not
better, in the other dimension as well. Here the first procedure
dominates the second, and ICERs cannot be calculated because no
cost increase will improve outcome. As has been done else-
where,25 specifying the presence of dominance as justification for
not calculating ICERs was considered ideal. However, we gave
partial credit for merely identifying one procedure as being both
less expensive and also better clinically than the alternative.
9. Was allowance made for uncertainty in the estimates of
costs and consequences? Authors should have addressed the un-
certainty associated with any observed cost or outcome differ-
ences, and they received partial credit for performing any statisti-
cal analyses at all. Full credit required providing appropriate
descriptions of central tendency (eg, means vs. medians) of cost
with standard deviations or interquartile ranges and of confidence
intervals around point estimates of outcomes frequencies (eg,
percent mortality) or statistical analyses (with parametric versus
nonparametric tests, log transformation, and so on) appropriate for
sample sizes and for cost data with possibly skewed distribu-
tions.26 Authors should also have distinguished differences that
were clinically or economically important but statistically nonsig-
nificant because of the small sample size from those that reflected
clinically or economically unimportant differences. We did not
require currently used approaches, such as generating confidence
intervals around calculable ICERs.27
As an adjunct or alternative to statistical analyses, we gave
credit for performing sensitivity analyses28 that estimated the
impact on hypothetic study results of varying values for key
parameters (eg, stabilizer costs) over reasonable ranges. New car-
diovascular and other procedures have learning curves.29 This
complicates assessment of the clinical and economic outcomes of
procedures that must be sufficiently mature to be reasonably eval-
uated but not yet so widely accepted as to preclude abandoning
them if justifiable. Furthermore, costs may decrease with accumu-
lating experience, even without improvements in outcome.30 Al-
though it was not required by the checklist, investigators could
have addressed the learning curve by separately analyzing results
from their early versus late MIDCAB experience and through
sensitivity analyses modeling hypothetical impacts on study results
of future changes in MIDCAB or other procedure results or costs
reflecting evolving trends.
10. Did the presentation and discussion of results include
issues of most concern to potential users? Although no study can
address all concerns of interest to all readers, discussion sections
needed to be reasonably comprehensive to receive full credit. For
example, discussions should have addressed all components of the
study question as originally asked. Conclusions also had to be
consistent with data-driven results; assertions of cost-effectiveness
required support by data on clinical effectiveness as well as cost.
Discussions should have properly summarized study strengths and
weaknesses and considered the impact of study limitations on the
strength of the conclusions. Studies that did not acknowledge their
failure to address key issues were not considered adequate. Ideally,
discussions should also have compared results with findings of
reports published at least 2 years earlier, acknowledging relevant
similarities and differences in study design, patient population,
cost perspectives, and so on. Studies should also have considered
the implications of their results for choices to be made between
MIDCAB and alternatives by decision makers with similar per-
spectives while also at least considering the study results’ broader
implications for decision makers with other perspectives.
Checklist Application and Data Analysis
Each reviewer independently answered the question of whether
each article adequately addressed each checklist item as: yes, no,
partially, or not applicable. After generating final ratings by re-
solving discrepancies through consensus, we assessed numbers of
items adequately addressed by each study. Because we appraised
all known studies meeting our inclusion criteria, there was no
larger universe of studies to which tests of statistical inference
performed on our own results would have applied.
Results
Review of the 92 titles, abstracts, or articles from our initial
MEDLINE search, plus results of other searches and review
of relevant citations and related article links, yielded 10
articles meeting our criteria for inclusion as comparative
economic analyses of MIDCAB. Of these, only 1 was a full
economic evaluation9 comparing both clinical effectiveness
(success of revascularization) and costs of competing strat-
egies. The other 9 studies were partial economic evalua-
tions, generally with inpatient complications as the only
clinical outcome measured.
All 10 studies were nonrandomized and generally com-
pared concurrent intrainstitutional series. Stated results gen-
erally favored PTCA, OPCAB, or MIDCAB over C-CAB
(Table 1). However, most studies had multiple weaknesses
(Table 2), reducing the validity of their conclusions. Al-
though most studies received partial credit on many items,
percentages of articles adequately addressing applicable in-
dividual checklist items ranged from 0% for item 4 (iden-
tifying relevant costs and consequences) to only 50% for
items 2 (comprehensive description of alternatives) and 5
(appropriate units). No studies followed up patients beyond
1 year, so item 7 (discounting) was universally not appli-
cable. Individual studies ranged from 0% to 67% in the
percentage of applicable items adequately addressed, with a
mean of just 24%. Only 2 studies adequately addressed
more than 50% of applicable items.
Chief among the methodologic problems was the wide-
spread failure to design or execute studies in which ob-
served outcome or cost differences could be reasonably
ascribed to treatment rather than to patient group differ-
ences. Several studies compared MIDCAB with OPCAB or
C-CAB without addressing the fact that included patients
undergoing OPCAB or C-CAB for multivessel disease
would not have been MIDCAB candidates. Two studies
violated intent-to-treat principles by excluding results of
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patients undergoing MIDCAB followed by other proce-
dures. Only 1 study compared rates of postdischarge reop-
erative procedures between a MIDCAB group and a control
group; another study followed up only MIDCAB patients
after discharge. The few studies that considered any post-
discharge outcomes at all did not clearly track admissions to
other centers.
Although most studies appeared to focus on hospital
costs, none specifically stated their analytic perspective.
Few studies specified their sources of cost data; others only
measured billed hospital charges. Some studies apparently
excluded certain major hospital costs (eg, MIDCAB stabi-
lizer purchase prices) in a manner not consistent with any
readily definable perspective. Costs of standby cardiopul-
monary bypass or of stabilizer reuse were generally not
addressed. No studies included costs of physician or physi-
cian assistant involvement. Although most studies included
costs from multiple calendar years, only 1 expressed them in
constant-year dollars. Even when it was possible, few stud-
ies calculated ICERs. Statistical analyses were limited, and
no studies reported results of sensitivity analyses. Discus-
sions were generally not comprehensive. Of 3 studies that
reported the purported cost-effectiveness of MIDCAB, none
included data sufficient to support their conclusions.
Discussion
Discussions of the principles of economic analysis have
appeared in the medical literature since 1977.5 We applied
a well-known 10-item checklist for evaluating economic
analyses9 to published comparisons of costs of MIDCAB
versus those of alternative procedures. We found minimal
adherence to basic analytic principles, with only 2 of 10
studies adequately addressing more than 50% of applicable
items. This finding mirrors results of general reviews of the
radiology31 and oncology32 literature.
Our own study had several limitations. Completeness of
our capture of relevant studies is unknown. However, the
search strategy described here should have captured virtu-
ally all English-language peer-reviewed MIDCAB cost
analyses. Appraisals such as ours are inherently subjective.
Criteria for distinguishing among adequate, partially ade-
quate, and inadequate handling of individual, often multi-
dimensional checklist items were difficult to specify pro-
spectively. However, these principles are laid out in
Drummond and coworkers’ checklist,9 which was designed
to promote objective assessment. Individual discrepancies
were easily resolved by consensus.
Checklist items were variable in their importance in
evaluating MIDCAB studies per se. We therefore could
neither generate defensible weighted composite scores for
individual studies nor specify score thresholds that would
distinguish high-quality studies. We may also have under-
estimated true study quality if perceived space constraints
discouraged authors from describing how they had actually
addressed various checklist issues. However, economic
analyses reporting guidelines9,10 dictate that investigators
should document the degree to which appropriate method-
ology supports their results. Finally, our unblinded evalua-
tion revealed investigator and institutional identities and
study results. However, neither of us had participated in any
TABLE 1. Individual MIDCAB comparative study descriptions
Appendix
reference
No. Patient accrual period Treatments compared
Control
group Outcome measures compared
Treatment
favored*
1 Aug 1995–Apr 1996 MIDCAB, C-CAB, PT, ST I Inpatient complications† PT
2 Jan 1995–Jul 1996 MIDCAB, C-CAB, PER I Inpatient complications,† repeat
revascularization procedures
MIDCAB
3 Jan–Aug 1996 MIDCAB, C-CAB I Inpatient complications† MIDCAB
4 Nov 1996–Nov 1997 OFF, C-CAB I Inpatient complications† OFF
5 Jan 1995–Dec 1996 MIDCAB, C-CAB I, H Inpatient complications,† 6-mo angina Mixed
6 Jan 1997–Jun 1998 MIDCAB, OPCAB, C-CAB I Inpatient complications† OPCAB,
MIDCAB
7 Nov 1996–Jun 1998 OFF, C-CAB I Inpatient complications† OFF
8 Nov 1996–Apr 1999 OFF, C-CAB E Inpatient complications† OFF
9 May 1997–Dec 1998 MIDCAB, OPCAB, C-CAB,
ECAB, PCAB
I Inpatient (?) reoperations Mixed
10 Jan 1995–Jul 1997 MIDCAB, C-CAB I, H None MIDCAB
E, Concurrent nonrandomized external control group; ECAB, on-pump coronary artery bypass by endoscopic thoracotomy; H, historical intrainstitutional
control group; I, concurrent intrainstitutional nonrandomized control group; OFF, off-pump coronary artery bypass by sternotomy or thoracotomy (not
separated); PCAB, on-pump coronary artery bypass by thoracotomy; PER, percutaneous transluminal coronary angioplasty (PTCA) with or without stenting
(not separated); PT, PTCA alone; ST, PTCA with stenting.
*Treatment favored by authors in their conclusions.
†Including mortality.
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of the investigations cited, nor did either of us have previous
clinical opinions regarding the procedures compared.
Despite these limitations, our analysis argues for greater
involvement of experts in cost analyses in study design and
execution, with increased awareness of relevant method-
ologic principles among investigators, manuscript review-
ers, and editors. We hope that such efforts will enhance
adherence to published guidelines in future MIDCAB stud-
ies. Although the impact of MIDCAB cost analyses may
decline if OPCAB replaces MIDCAB as the dominant off-
pump surgical procedure,33 our recommendations for de-
signing studies and reporting of their results apply equally
to other surgical procedures. In the current environment,
economic considerations may be expected to continue to
influence medical resource allocation. Only with greater
methodologic rigor can published economic analyses be
expected to reasonably inform health care policy decisions
in cardiovascular surgery and other fields.
We acknowledge review of the manuscript by Will Holling-
worth, PhD, and Margaret Allen, MD. Assistance with manuscript
preparation was provided by Kathryn Calderwood, Eli Chiaviello,
and Lucy Lanot.
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